
PVLA Stock Forecast & Price Target
PVLA Analyst Ratings
Bulls say
Palvella Therapeutics is viewed positively because its lead asset, QTORIN 3.9% rapamycin gel, has already cleared a major clinical hurdle in mLMs, where Phase 3 SELVA met its primary and all prespecified secondary endpoints, and FDA accepted the NDA for Priority Review with a February 28, 2027 PDUFA date. The thesis is strengthened by a rare-disease platform with limited competition, a localized and non-immunosuppressive delivery approach, and a market-creation strategy that could address multi-thousand-patient opportunities, with modeled gross peak sales of about $1.4B for mLMs, $2.1B for cVMs, and $900M each for CSAs and DSAP. Additional upside comes from a focused commercial launch setup, 166 mapped sites, roughly 400 initial targets, and multiple upcoming catalysts in 4Q26 and 2027 that could broaden the platform beyond the first approval.
Bears say
Palvella Therapeutics is facing a fundamentally fragile setup because its novel QTORIN platform still has to prove that localized delivery can generate consistent, clinically meaningful results across multiple indications and payloads. The lead programs rest on single-arm, baseline-controlled studies and novel endpoints, while FDA uncertainty, narrower-label risk, and prior delays in CMC or inspection issues all raise the odds of added studies and slower approval. Even if approved, commercialization is challenged by a small specialized patient base, entrenched cheaper alternatives, a $250.6M cash position paired with a runway of only at least 12 months, likely dilution, and 8.0%-9.8% Ligand royalties that compress economics.
This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PVLA Analyst Forecast & Price Prediction
Start investing in PVLA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Palvella Therapeutics Inc (PVLA) Forecast
PVLA Analyst Forecast & Price Prediction
Start investing in PVLA
Order type
Buy in
Order amount
Est. shares
0 shares